Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment

NCT01479244 is registered in ClinicalTrials.gov with Galena Biopharma, Inc. as lead sponsor.

NCT NCT01479244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01479244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Lead sponsor
Galena Biopharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
September 21, 2016
Enrollment
758 (actual)
Sites
197

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer with low to intermediate her2 expression